Payment overview · 2025
General Payments
$1,581.82
84 reported records · 15 companies
Healthcare provider profile · identity verified
Loren Carroll, MD
Allopathic & Osteopathic Physicians|Family Medicine · JACKSON, TN · NPI 1104168178
Verified facts
What the public records show
CMS Open Payments records show Loren Carroll, MD received $1,581.82 in general payments during 2025 across 84 reported records.
Novo Nordisk Inc accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Qulipta, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 2184 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $289.13 | 18.3% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $246.01 | 15.6% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $219.33 | 13.9% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $141.60 | 8.9% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $140.39 | 8.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $139.88 | 8.8% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.40 | 8.6% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $111.49 | 7.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.02 | 2.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.47 | 1.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.22 | 1.4% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$21.80 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.05 | 1.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.35 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.68 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,470.33 | 83 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $253.35 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $166.23 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $140.69 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $140.39 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $139.88 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $128.21 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.53 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $105.32 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $105.32 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.11 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $80.09 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $72.01 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $72.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.77 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 2184 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 189 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 128 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 242 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
138 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
189 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
46 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
242 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
208 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
115 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
128 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
113 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
128 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
106 | 105 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
2184 | 128 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
88 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 3621 | 226 |
| Atorvastatin Calcium | Atorvastatin Calcium | 3406 | 269 |
| Potassium Chloride | Potassium Chloride | 2871 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2659 | 175 |
| Famotidine | Famotidine | 2399 | 165 |
| Pantoprazole Sodium | Pantoprazole Sodium | 2328 | 170 |
| Eliquis | Apixaban | 2184 | 128 |
| Divalproex Sodium | Divalproex Sodium | 1868 | 81 |
| Lisinopril | Lisinopril | 1745 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 1673 | 174 |
| Mirtazapine | Mirtazapine | 1612 | 89 |
| Omeprazole | Omeprazole | 1562 | 180 |
| Memantine Hcl | Memantine Hcl | 1561 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 1532 | 112 |
| Sertraline Hcl | Sertraline Hcl | 1467 | 90 |
| Buspirone Hcl | Buspirone Hcl | 1433 | 91 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1432 | 124 |
| Donepezil Hcl | Donepezil Hcl | 1428 | 75 |
| Citalopram Hbr | Citalopram Hydrobromide | 1371 | 74 |
| Trazodone Hcl | Trazodone Hcl | 1295 | 111 |
| Losartan Potassium | Losartan Potassium | 1122 | 129 |
| Quetiapine Fumarate | Quetiapine Fumarate | 1116 | 62 |
| Metformin Hcl | Metformin Hcl | 1110 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 949 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 946 | 80 |
| Simvastatin | Simvastatin | 938 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 899 | 113 |
| Duloxetine Hcl | Duloxetine Hcl | 822 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 822 | 58 |
| Levetiracetam | Levetiracetam | 795 | 51 |
| Baclofen | Baclofen | 700 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 700 | 87 |
| Allopurinol | Allopurinol | 686 | 61 |
| Gabapentin | Gabapentin | 682 | 99 |
| Carvedilol | Carvedilol | 669 | 73 |
| Risperidone | Risperidone | 636 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 599 | 25 |
| Olanzapine | Olanzapine | 555 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 535 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 483 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 479 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 472 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 468 | 34 |
| Montelukast Sodium | Montelukast Sodium | 457 | 60 |
| Meloxicam | Meloxicam | 455 | 60 |
| Dicyclomine Hcl | Dicyclomine Hcl | 454 | 24 |
| Spironolactone | Spironolactone | 445 | 31 |
| Prednisone | Prednisone | 418 | 101 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 395 | 50 |
| Alendronate Sodium | Alendronate Sodium | 393 | 28 |
| Lorazepam | Lorazepam | 372 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 371 | 119 |
| Oxybutynin Chloride | Oxybutynin Chloride | 360 | 19 |
| Xarelto | Rivaroxaban | 355 | 17 |
| Midodrine Hcl | Midodrine Hcl | 348 | 37 |
| Tramadol Hcl | Tramadol Hcl | 348 | 45 |
| Primidone | Primidone | 344 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 331 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 329 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 317 | 26 |
| Haloperidol | Haloperidol | 305 | 12 |
| Finasteride | Finasteride | 295 | 26 |
| Januvia | Sitagliptin Phosphate | 283 | 26 |
| Myrbetriq | Mirabegron | 279 | 15 |
| Lamotrigine | Lamotrigine | 267 | 21 |
| Lansoprazole | Lansoprazole | 259 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 242 | 44 |
| Sucralfate | Sucralfate | 239 | 15 |
| Aripiprazole | Aripiprazole | 233 | 17 |
| Rivastigmine | Rivastigmine | 229 | 13 |
| Metformin Hcl Er | Metformin Hcl | 224 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 89 |
| Diclofenac Sodium | Diclofenac Sodium | 223 | 51 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 223 | 45 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 220 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 215 | 23 |
| Azithromycin | Azithromycin | 209 | 134 |
| Jardiance | Empagliflozin | 208 | 19 |
| Metolazone | Metolazone | 198 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 194 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 193 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 193 | 65 |
| Ondansetron Hcl | Ondansetron Hcl | 192 | 71 |
| Bupropion Xl | Bupropion Hcl | 191 | 22 |
| Farxiga | Dapagliflozin Propanediol | 189 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 185 | 25 |
| Warfarin Sodium | Warfarin Sodium | 185 | 20 |
| Rivastigmine | Rivastigmine Tartrate | 183 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 181 | 33 |
| Topiramate | Topiramate | 181 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 177 | 17 |
| Ezetimibe | Ezetimibe | 176 | 13 |
| Propranolol Hcl | Propranolol Hcl | 172 | suppressed |
| Levemir | Insulin Detemir | 166 | 32 |
| Lidocaine Hcl | Lidocaine Hcl | 165 | 95 |
| Diltiazem 24hr Er | Diltiazem Hcl | 163 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 162 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 159 | 87 |
| Celecoxib | Celecoxib | 157 | suppressed |
| Gemfibrozil | Gemfibrozil | 154 | suppressed |
| Cephalexin | Cephalexin | 153 | 72 |
| Methocarbamol | Methocarbamol | 153 | 29 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 152 | suppressed |
| Alprazolam | Alprazolam | 149 | 32 |
| Sevelamer Carbonate | Sevelamer Carbonate | 147 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 144 | 30 |
| Benazepril Hcl | Benazepril Hcl | 143 | 14 |
| Bupropion Hcl | Bupropion Hcl | 143 | suppressed |
| Glimepiride | Glimepiride | 143 | 25 |
| Tradjenta | Linagliptin | 140 | suppressed |
| Ozempic | Semaglutide | 139 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 48 |
| Linzess | Linaclotide | 138 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 137 | 61 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 17 |
| Promethazine Hcl | Promethazine Hcl | 137 | 35 |
| Ibuprofen | Ibuprofen | 133 | 29 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 130 | 14 |
| Clonazepam | Clonazepam | 129 | 22 |
| Rexulti | Brexpiprazole | 128 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 127 | suppressed |
| Hydrocortisone | Hydrocortisone | 127 | 12 |
| Nifedipine Er | Nifedipine | 126 | 13 |
| Latanoprost | Latanoprost | 124 | 28 |
| Sotalol | Sotalol Hcl | 124 | suppressed |
| Verapamil Er | Verapamil Hcl | 121 | suppressed |
| Atenolol | Atenolol | 120 | 15 |
| Calcitriol | Calcitriol | 120 | suppressed |
| Trulicity | Dulaglutide | 115 | suppressed |
| Digoxin | Digoxin | 114 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 114 | 16 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 113 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 110 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 110 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 110 | 36 |
| Divalproex Sodium Er | Divalproex Sodium | 109 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 109 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 107 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 106 | 105 |
| Torsemide | Torsemide | 106 | suppressed |
| Nystatin | Nystatin | 105 | 63 |
| Fenofibrate | Fenofibrate | 103 | 13 |
| Fluconazole | Fluconazole | 100 | 54 |
| Bumetanide | Bumetanide | 99 | 14 |
| Calcium Acetate | Calcium Acetate | 96 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 96 | suppressed |
| Methotrexate | Methotrexate Sodium | 96 | suppressed |
| Nystop | Nystatin | 95 | 45 |
| Galantamine Hbr | Galantamine Hbr | 94 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 94 | 65 |
| Gemtesa | Vibegron | 93 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 91 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 91 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 90 | 18 |
| Austedo | Deutetrabenazine | 88 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 84 | 23 |
| Diazepam | Diazepam | 84 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 83 | suppressed |
| Methimazole | Methimazole | 83 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 62 |
| Lactulose | Lactulose | 81 | 25 |
| Oxcarbazepine | Oxcarbazepine | 78 | suppressed |
| Acyclovir | Acyclovir | 76 | suppressed |
| Ertapenem | Ertapenem Sodium | 75 | 39 |
| Mupirocin | Mupirocin | 74 | 46 |
| Methylprednisolone | Methylprednisolone | 73 | 60 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 72 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 71 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 20 |
| Scopolamine | Scopolamine | 71 | suppressed |
| Telmisartan | Telmisartan | 71 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 70 | suppressed |
| Lidocaine | Lidocaine | 70 | 11 |
| Lubiprostone | Lubiprostone | 69 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 66 | suppressed |
| Nyamyc | Nystatin | 66 | 25 |
| Valsartan | Valsartan | 62 | suppressed |
| Irbesartan | Irbesartan | 61 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 61 | suppressed |
| Lamotrigine Er | Lamotrigine | 60 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 59 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 57 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 57 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 57 | 20 |
| Novolog | Insulin Aspart | 57 | 15 |
| Pregabalin | Pregabalin | 57 | 14 |
| Brimonidine Tartrate | Brimonidine Tartrate | 56 | 11 |
| Levofloxacin | Levofloxacin | 56 | 43 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 55 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 41 |
| Venlafaxine Hcl | Venlafaxine Hcl | 54 | suppressed |
| Ondansetron Odt | Ondansetron | 53 | 31 |
| Premarin | Estrogens, Conjugated | 53 | suppressed |
| Zonisamide | Zonisamide | 53 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 52 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 52 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 49 | 20 |
| Naproxen | Naproxen | 49 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 49 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 48 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Lovastatin | Lovastatin | 46 | suppressed |
| Novolin R | Insulin Regular, Human | 46 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 37 |
| Cefdinir | Cefdinir | 45 | 40 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 45 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Rybelsus | Semaglutide | 44 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Clonidine | Clonidine | 43 | suppressed |
| Nateglinide | Nateglinide | 43 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 42 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 42 | suppressed |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Glipizide | Glipizide | 41 | 11 |
| Carbamazepine | Carbamazepine | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Ramipril | Ramipril | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 38 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 38 | 25 |
| Cilostazol | Cilostazol | 37 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 37 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Anastrozole | Anastrozole | 35 | suppressed |
| Brilinta | Ticagrelor | 35 | suppressed |
| Nabumetone | Nabumetone | 35 | suppressed |
| Levemir Flexpen | Insulin Detemir | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 28 |
| Folic Acid | Folic Acid | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Lumigan | Bimatoprost | 32 | suppressed |
| Valproic Acid | Valproic Acid | 32 | suppressed |
| Amantadine | Amantadine Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | 12 |
| Tiotropium Bromide | Tiotropium Bromide | 31 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Ramelteon | Ramelteon | 30 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 30 | 11 |
| Levalbuterol Hcl | Levalbuterol Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Insulin Aspart | Insulin Aspart | 28 | 13 |
| Santyl | Collagenase Clostridium Hist. | 28 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Erythromycin | Erythromycin Base | 27 | 14 |
| Klor-Con 10 | Potassium Chloride | 27 | suppressed |
| Ssd | Silver Sulfadiazine | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 14 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 23 |
| Budesonide | Budesonide | 24 | suppressed |
| Cyclosporine | Cyclosporine | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Qulipta | Atogepant | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 23 | 18 |
| Austedo Xr | Deutetrabenazine | 22 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 22 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | 14 |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 22 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 22 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 22 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 21 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 21 | suppressed |
| Lamivudine | Lamivudine | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | 13 |
| Valacyclovir | Valacyclovir Hcl | 21 | 18 |
| Acarbose | Acarbose | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Mirabegron Er | Mirabegron | 20 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 20 | 17 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Galantamine Er | Galantamine Hbr | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | 13 |
| Pilocarpine Hcl | Pilocarpine Hcl | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | 11 |
| Nitroglycerin | Nitroglycerin | 16 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 12 |
| Haloperidol Decanoate | Haloperidol Decanoate | 15 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | 12 |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 13 | suppressed |
| Risperidone Odt | Risperidone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Matzim La | Diltiazem Hcl | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | 11 |
| Cefepime Hcl | Cefepime Hcl | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,581.82 · 84 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, ELIQUIS, FARXIGA, IBSRELA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VALTOCO, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error